Big Pharma's Patent Cliff
Tallying up the fallout from patent expirations
This article is for subscribers only.
Drugs going off-patent in 2014 contribute just under $50 billion in pharmaceutical industry revenue. Not all products losing protection face imminent competition from generics; biological products and drugs delivered by devices are best poised to extend their money-spinning streak.